A director at Securitas AB bought 1,430 shares at 139.800SEK and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
The Q1 reporting season is in full swing, with results from Catena, Entra, Pandox and Wihlborgs in the past week. In addition, Aurora Eiendom announced a proposal to delist from Euronext Growth Oslo. The weighted-average implied EBITDA yields on the stocks we cover are 5.00% for 2025e and 5.31% for 2026e.
MTG’s 2025 organic growth outlook of 3–7% YOY was a key positive in an otherwise difficult market for mobile gaming, in our view. However, the adj. EBITDA margin guidance of 21–24% fell shy of our expectation. We have only finetuned our 2025–2026e sales, but cut adj. EBITDA by 18–7% on the margin outlook, with some upside potential if synergies from the Plarium acquisition should materialise in 2025. We reiterate our BUY, but have lowered our target price to SEK130 (140).
Solid Q1 results included a 7% consensus beat on PFPM, driven by the top line and NOI margin. We reiterate our HOLD, as we consider Catena overcapitalised and are concerned about the lack of attractive investment opportunities, particularly given a slow project market (historically the company’s highest ROI investment). In addition, we believe the valuation looks stretched versus its European logistics peers. However, we have raised our target price to SEK480 (470) and our 2026–2027e FFOps by 2–...
At the ISHLT 2025 meeting, XVIVO presented the final 12-month results from its European NIHP2019 heart transplantation trial, further validating the benefits of its Heart Assist Transport system. The data showed a 38% reduction in severe post-transplant complications (33% for XVIVO vs 47% for cold
The markets were much quieter following the Easter break, with limited news; however, the names we cover saw their shares up 2.6% on average, with Atrium Ljungberg (7.1%), SBB (7.1%) and Pandox (4.8%) the top performers. JM released its Q1 results and we reiterated our BUY, believing it has passed the earnings trough, while we reiterated our HOLDs on Corem and Fabege following their quarterly reports. The weighted-average implied EBITDA yields on the stocks we cover are 5.04% for 2025e and 5.34%...
Q1 sales were SEK219m (up 18% YOY; we forecast 11%, consensus 13%), with an EBITDA margin of 20% (we forecast 23%). After a quarter marked by regulatory progress, the key potential milestone ahead remains CE approval of the heart technology in 2025e, in our view. We reiterate our BUY and SEK520 target price.
XVIVO began 2025 with solid momentum, reporting Q1 net sales of SEK 218.6m (+18% YoY, +14% in local currencies), slightly ahead of CSS (SEK213m) and in line with BG estimates (SEK220m), driven by 14% organic and 2% acquired growth. Thoracic, although representing a -5% dop QoQ, remained the main gr
Q1 will be the first quarter including the transformative Plarium acquisition (consolidated from 1 February), set to roughly double MTG’s revenue and adj. EBITDA. Our impression is organic growth trends have held up alright in Q1; however, the recent strengthening of the SEK has prompted a ~9% cut to our 2025–2026e revenue and EBITDA. We have lowered our target price to SEK140 (150) but reiterate our BUY.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.